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Abstract Acquired aplastic anemia (AA) and paroxysmal
nocturnal hemoglobinuria (PNH) are interrelated ultra-rare
diseases. Quality of life (QoL) evaluation tools used in studies
for AA and PNH are unspecific and designed for cancer pa-
tients (e.g., the European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire, EORTC
QLQ-C30). Given the complexity of AA and PNH, variation
in symptoms and treatments, younger age of many patients,
and the fact that AA and PNH are not classified as malignant
diseases, it is likely that cancer-specific questionnaires are
inappropriate. We generate an AA/PNH-specific QoL ques-
tionnaire (QLQ-AA/PNH), performed according to EORTC
guidelines. QoL issues were obtained from the literature and
interviews with patients and physicians (phase I), then ranked
by patients and physicians. In phase II, items were created.
Patients in more than 25 German and Swiss cities were
interviewed face to face. In phase I, interviews of 19 patients
and 8 physicians specialized in AA/PNH treatment resulted in
649 QoL issues; these were condensed to 175 and graded ac-
cording to their importance by 30 patients and 14 physicians
(phase II). Five physicians took part in phases I and II.
Altogether, 97 issues were rated important. Twelve EORTC
QLQ-C30 items were not rated important, while several new
QoL aspects were brought up. Modifications in wording and
phrasing led to two questionnaires with 77 items regarding
general QoL aspects and 20 items regarding medical care.
Important QoL aspects of PNH/AA patients are inappropriately
captured with available QoL tools. Developing a new QoL
questionnaire specific for this patient group is warranted.
Keywords Aplastic anemia . Paroxysmal nocturnal
hemoglobinuria . Quality of life . Bonemarrow failure
syndromes
Introduction
Both acquired aplastic anemia (AA) and paroxysmal noctur-
nal hemoglobinuria (PNH) are ultra-rare diseases with a yearly
incidence within the western hemisphere of 1.3 to 2 per mil-
lion [1, 2]. The number of patients newly developing AA,
PNH, or overlap syndromes, e.g., within Germany, is estimat-
ed to be 250 per year; however, not all of them are properly
diagnosed so that the actual number of newly diagnosed pa-
tients is somewhat lower. Age distribution for AA shows a
bimodal distribution with a peak in young adults, while the
mean age at diagnosis of PNH is between 30 and 45 years.
PNH and AA are interrelated diseases and cannot be viewed
separately as both belong to the group of bone marrow failure
syndromes (BMFS) [3, 4].
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For patients with PNH, the median overall survival before
the introduction of the complement inhibitor eculizumab was
between 10 and 22 years with about a third of patients dying
within the first 10 years after diagnosis [5–8]; whereas now,
basically all patients survive the first year and data from the
long-term safety and efficacy of Eculizumab in 195 patients
with hemolytic PNH show that consequent complement in-
hibitor treatment results in a 3-year survival estimate of
97.6%, i.e. as in age-matched controls [9]. Allogeneic bone
marrow transplantation (BMT), rarely used in patients with
PNH, is the treatment of choice for patients below the age of
40 with severe AA and an available HLA-identical sibling [2].
Treatment decisions in AA for patients without an HLA-
identical sibling, older patients, or patients not responding to
first-line immunosuppressive therapy (IST) are more complex
and involve further courses of IST, BMT from alternative
donor sources, or experimental treatment approaches [2, 10].
While considerable research has been performed and pub-
lished with regard to the pathophysiology and treatment of
AA and PNH, much less is known regarding both diseases’
psychosocial issues and their impact on quality of life (QoL).
So far, the only reports on QoL for PNH stem from the
original eculizumab trials (TRIUMPH and SHEPHERD)
[11, 12] using the European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire (EORTC
QLQ)-C30 [13] including 87 patients in the TRIUMPH and
93 patients in the SHEPHERD trial. In addition to QoL,
fatigue as a major clinical symptom of patients with PNH
was prospectively evaluated in both trials using the
Functional Assessment of Chronic Illness Therapy Fatigue
Instrument (FACIT-Fatigue). Both trials demonstrated that,
compared to placebo, treatment with eculizumab resulted in
clinically significant improvements in regard to QoL and
fatigue.
In another small series with 29 patients, fatigue and abdom-
inal pain were reported as relevant QoL issues [14].
Both questionnaires, the EORTCQLQ-C30 and the FACIT-
Fatigue are now routinely used within the PNH registry, a
prospectively documenting international registry that has been
established following a post-marketing commitment of the
eculizumab manufacturer Alexion Pharmaceuticals Inc., re-
quested by both the EMA (European Medicines Agency) and
the FDA (Food and Drug Administration) [15].
In AA, QoL assessment is even less standardized and
research so far mainly investigated sequelae from bone mar-
row transplantation [16–18]. Even large studies on treat-
ment outcome mainly used surrogate parameters such as
hemoglobin levels and other blood counts or survival to
investigate patient burden, but QoL was not measured
with validated self-assessed instruments by patients
[19–21]. Few studies evaluated QoL aspects in non-
transplanted AA patients [22, 23], and there is only one report
comparing QoL aspects of patients after BMT to those
receiving immunosuppressive therapy retrospectively [24].
However, the QoL evaluation tools used in all these studies
were again either surrogate parameters such as treatment tox-
icity, transfusions and drug requirements, hematologic counts
or rates of employment after long-time follow-up or were
unspecific for AA patients and transferred from evaluations
in cancer patients, e.g., by using the quality-adjusted time
without symptoms and toxicity (Q-TWiST) methodology.
Given the complexity of AA and PNH, the variation in
symptoms and different treatment approaches (IST, BMT,
complement inhibition with eculizumab and others and even-
tually sequences of all in some patients), the young age of the
patients, and the fact that marrow failure syndromes are not
classified as malignant diseases, it is likely that the cancer-
specific tools used so far are inappropriate to adequately as-
sess the QoL and illness intrusiveness in this group of patients.
Only few experts in the field of PNH can be found and even
within the hematologic community, PNH and AA might be
underestimated in regard to morbidity and mortality, leading
to inadequate or delay of treatment.
We hypothesize that lack of adequate information and
counseling, lack of support systems, and the fragmentation
of services as well as the varying quality of medical services
lead to a profound impact on psychosocial well-being of pa-
tients with AA/PNH. Physicians probably often underestimate
the resulting disease burden and impacts on QoL.
Based on these considerations, we therefore initiated the
development of a AA/PNH-specific QoL instrument (QLQ-
AA/PNH) according to EORTC guidelines [25]. The objec-
tives of this study were to identify symptoms and QoL issues
reported by patients with AA and/or PNH and identified by
physicians working as specialists in the field of AA/PNH
treatment and to determine how both groups rate their impor-
tance. According to the EORTC quality of life group (EORTC
QLG), an issue is a term used to describe and identify a QoL
domain that is potentially affected by a disease (malignancy)
and/or its treatment [26].
Methods
Phase I (generation of issues)
Literature review
From March 2012 to May 2012, a systematic literature search
was performed using the Medline database and the Website of
the American Society of Hematology (ASH) to search the
abstracts of the annual ASH meeting. Search criteria included
the following terms: aplastic anemia, aplastic syndrome, par-
oxysmal nocturnal hemoglobinuria, plus one of the following
search terms: quality of life, therapy, bone marrow
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transplantations, immunosuppression, antithymocyte globulin
(ATG), eculizumab, patient perspective, symptoms.
Medline search was restricted to articles published between
1985 and 2012, and abstracts from the annual ASH meeting
were restricted to be published between 2004 and 2012.
All publications and abstracts were carefully searched for
QoL issues mentioned and QoL instruments used.
Interviews of patients and physicians specialized in treatment
of PNH/AA
Because of the rarity of the disease, special efforts were made
to include patients with different disease stages, educational
background, and geographical region.
Patients for phase I interviews were approached mainly via
physicians and via patient advocacy groups. The internet fo-
rum www.pnh-aa.info, founded as a self-help initiative, pro-
vides a bulletin board for registered members with links to
reference centers and specialists and downloadable informa-
tion brochures as well as the registered association
Aplastische Anämie e.V. (www.aplastische-anaemie.de),
which is a patient advocacy group and part of the German
Leukemia and Lymphoma Support Group (DLH). Both self-
help groups announced our research projects on their website
and encouraged patients to take part.
Physicians known as specialists for treatment of AA/PNH,
e.g., actively involved in the development of treatment guide-
lines within Germany, Austria, and Switzerland, were
contacted by two of the authors (THB and JP) and patients
treated within centers were approached by these physicians.
Additional patients were enrolled during two patient con-
ferences, through a Facebook website of one of the patients
and by word-of-mouth from other patients.
Ethical approval was obtained from the ethical committee
of the Medical Faculty RWTH Aachen University, and an
informed consent letter, which was signed by each participat-
ing patient, was phrased in consultation with the data safety
manager of the University Hospital RWTH Aachen.
After patients sent back their signed informed consent, one
of the authors (MG) contacted them and interviews were
appointed. Most patients wanted to be interviewed at home
alone; however, two interviews were done in pairs and one
group of patients (n = 4) was interviewed together in the form
of a focus group.
The interviews were open and qualitative. At the beginning
of each interview, patients were asked to give a brief overview
of their disease history including first symptoms, time to first
physician contact, time to diagnosis, and treatment history.
Patients were subgrouped into those with predominant AA
features, predominant PNH features, and those with overlap-
ping PNH/AA features. In addition, patients were asked to
give details regarding their supportive care needs (e.g., infor-
mation, support by medical staff, psychosocial counseling,
and patient support groups) and potential problems experi-
enced due to the non-specificity of symptoms and the local
healthcare provision (e.g., delay in diagnosis, lack of local
availability of disease-specific experts, appreciation of QoL
problems by healthcare professionals).
Patients were invited to report about the diseases’ impact
on their quality of life without restricting themselves. All in-
terviews were audio-recorded and subsequently transcribed
verbatim. During the focus group interview, issues were re-
corded on a flip chart by the investigator (MG) and discussed
within the group. The session was videotaped and subsequent-
ly transcribed in order not to miss any potential issue that was
raised. Two reviewers then independently analyzed the tran-
scripts to identify QoL issues mentioned by the patients.
Identified issues were then compared and kept if both re-
viewers identified them as potentially affecting QoL.
Physician interviews were performed accordingly. With the
exception of one interview, which was done by telephone, all
were done in person by one author (MG). Issues raised by the
physicians were then compared to the already collected issues
derived from patient interviews and new issues were added to
the compilation.
Issues were sorted according to their content into separate
categories: physical, psychological, social, financial,
healthcare/therapy related. Three reviewers (MG, SS, JP) sep-
arately evaluated each issue and rated them as follows: Bkeep^
(keep issue as is), Bchange^ (keep issue, but rephrase),
Bdelete^ (delete issue). Issues rated Bkeep^ or Bchange^ from
≥2 reviewers were kept, whereas issues rated Bdelete^ from all
three reviewers were deleted without further discussion.
Issues rated Bkeep^ or Bchange^ in addition two times
Bdelete^ were kept if the reviewer who had performed the
interviews rated them relevant after discussion with the other
two reviewers.
Phase II (rating of issues)
Review and rating of issues
From the interviews, a list of QoL issues was generated ac-
cording to [25]. Within a semistructured interview, patients—
different from those in phase I—and physicians—five also
being interviewed in phase I—were asked to prioritize the
25most salient issues and rate all issues on a Likert scale (very
important (4 points), important (3 points), moderately impor-
tant (2 points), unimportant (1 point)).
Issues were considered relevant with a high priority for
inclusion if ≥2 of the following four criteria were fulfilled:
The mean rating of an issue by the total patient sample was
≥2.0; the mean rating of a patient subgroup (AA, PNH/AA, or
PNH) was ≥2.5; ≥20% of patients ranked an issue among the
top 25 issues; ≥ 30% of physicians ranked an issue among the
top 25 issues. Patients and physicians were also asked if any
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issues were missing. In contrast to EORTC guidelines, pa-
tients and physicians were asked to rate issues as being im-
portant or not considering the whole course of their disease
and not just the last couple of weeks. This was done because
PNH and AA patients often experience their diseases as a
chronic, long-lasting state with various Bdisease flares^ and
patients after bone marrow transplantation might experience
completely different disease features and treatment-related
morbidities before versus after the transplantation procedure.
Generation of items
All issues fulfilling the abovementioned criteria were reworded
into items so that they can be completed with the same re-
sponse categories as it is required for a self-administered ques-
tionnaire. The wording was suggested by one author (MG) and
reviewed by two authors (SS, JP) until a consensus was
reached.
All interviews, recordings, transcriptions, and generation of
issues and items were done in German. For the purpose of
publication this manuscript translation of issues and items into
English language was done by one author (JP) with review
and approval by all other authors. Final translation of items of
the final questionnaire into English and other languages will
be performed according to EORTC guidelines [25].
Comparison with EORTC QLQ-C30
The issues generate in phase I were compared with the first 28
items of the EORTC QLQ-C30, omitting the two general
items (BHow would you rate your overall health during the
past week?^ and BHow would you rate your overall quality of
life during the past week?^). This was done in order to eval-
uate (1) which EORTC QLQ-C30 items are considered im-
portant for AA/PNH patients, (2) which EORTC QLQ-C30
items are considered to be unimportant, and (3) which issues
are important and relevant for AA/PNH patients and are not
covered by the EORTC QLQ-C30.
Results
Literature review
QoL in AA patients
While the importance of exact assessment of QoL in AA pa-
tients has been stressed by several authors [23, 27], no specific
methods have been established so far and even a recently
published Cochrane analysis comparing the outcome of stem
cell transplantation and immunosuppressive therapy in AA
patients had to admit that BHealth-related quality of life
questionnaires were not used in any of the included studies^
they analyzed [28].
Our literature review identified a total of 17 reviews and
studies performed between 1984 and 2012 in which QoL-
related parameters in AA patients were reported (Table 1). In
13 of them, only surrogate parameters such as hemoglobin
levels, the ability to return to work, or general functional
scores such as the Karnofsky performance status scale were
used [19–23, 29–36]. Only 4 studies assessed QoL by using
questionnaires such as the EORTC QLQ-C30 or the SF36,
and one study [24] compared differences in QoL between
the two main treatment modalities, immunosuppression, and
stem cell transplantation, using the quality-adjusted time with-
out symptoms and toxicity (Q-TWiST) methodology.
QoL in PNH patients
Six publications/studies reporting QoL and/or treatment out-
comes in PNH patients could be identified (Table 2). The most
reliable data on QoL stem from the pivotal eculizumab trials
called TRIUMPH and SHEPHERD [11, 12] in which the
EORTC QLQ-C30 questionnaire was used. Both trials also
included the FACIT-Fatigue instrument after it was realized in
the first 11 patients treated with eculizumab [37] in which only
the C30 questionnaire had been used to assess QoL that fatigue
was a major factor as well and should be measured in more
detail. Two publications reported the outcome of PNH patients
after allogeneic stem cell transplantation, and in these only
surrogate parameters such as the occurrence of graft-versus-
host disease, the normalization of blood counts, and survival
data were discussed with regard to QoL aspects [38, 39].
Patient and physician interviews
Patient and physician samples
Individual patients in more than 25 German and Swiss cities
were visited and personally interviewed.
During phase I, 19 patients (Table 3) and eight physicians
specialized in treatment of AA/PNHwere interviewed. Fifteen
of the patients were female, and patients with either AA or
PNH/AA comprised the majority of patients (n = 9 and n = 6),
while 4 suffered from PNH without AA symptoms. Median
age at diagnosis was 29.1 years (range 17.0–50.3 years). At
the time of the interviews, the median age was 42.1 years. The
median time from the occurrence of first disease-specific
symptoms until final diagnosis was 14 months with a maxi-
mum duration of more than 5 years (range 0–61 months).
Other sociodemographic characteristics and disease-specific
features are given in Table 3.
All of the eight physicians were hematologists by training,
seven worked in a clinic; four of them were consultants, three
were heads of hematology or stem cell transplantation
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departments, and one was a registered hematologist working
in a private office. Six physicians were from Germany, one
from Switzerland, and one from Austria.
Based on the experiences from phase I, special efforts were
made to include patients with a more heterogeneous distribu-
tion regarding sex, disease, and time since diagnosis in phase
II. Thirty patients were contacted and agreed to participate, 10
of each disease entity, and half of them being male. Their
median age at diagnosis was 31.3 years and their median
age at the time of the interview was 43.7 years. The median
time from first disease-specific symptom to final diagnosis
was 4 months (range 0–61 months).
Fourteen physicians participated in phase II (of whom five
also took part in phase I), all of them working in a clinic at a
university hospital (four as head of the respective department,
ten as consultants), 13 from Germany, and one from Austria.
QoL issues
Out of the interviews in phase I, 649 QoL issues were derived.
Similar issues were combined into one, so that the list could be
condensed to 175 separate issues. The majority (141/175)
concerned general health-related QoL problems faced by pa-
tients with AA and/or PNH, while the remaining 34 issues
applied to problems experienced with healthcare (HC). It
was therefore decided to develop two questionnaires, one for
QoL and one for HC.
Relevance of issues
Of the 175 issues derived from phase I, 97 issues were rated
important (see Supplementary Table 5) according to at least
two relevance criteria (see rating of issues within the
BMethods^ section). Of these 97 issues, 77 concerned QoL
and 20 healthcare problems.
Fifteen issues met all four relevance criteria, 31 issues met
three criteria, and the remaining 51 issues met two criteria.
Neither patients nor physicians mentioned any missing issue.
Differences between AA and PNH patients
In general, issues were rated comparable between patients
with AA compared to patients with PNH. The only QoL issue
rated >2 points higher by patients with AA compared to pa-
tients with PNH was Bfear of therapy failure.^ In contrast,
PNH-only patients rated the QoL issues Bappearance^ and
Bsleep disorder/disturbance^ >2 points higher.
In regards to healthcare issues, PNH patients rated the issues
Bit helps having a personal bond with my primary doctor^
(individual support), Bit is important having doctors agreeing
on treatment^ (physician network), Bgetting a second opinion^,
and Bproblems within the social legislation^ >2 points higher
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Comparison with the EORTC QLQ-C30 issues
Comparison of the EORTC QLQ-C30 items with the 175
issues generated in phase I revealed that only 16 of them were
brought up or rated as important by AA and/or PNH patients.
Five EORTC QLQ-C30 items were not mentioned at all—
these being items rather typical for cancer patients or often
experienced during chemotherapy such as lack of appetite,
constipation or difficulties remembering things—while seven
others were mentioned during the interviews in phase I but
rated as unimportant in phase II (Table 4).
Generation of items
Modifications in phrasing finally led to two questionnaires:
one with 77 items regarding QoL and one with 20 items re-
garding healthcare.
Discussion
Here, we report the first two phases of the generation of a
specific QLQ-AA/PNH assessment tool, which resulted in
the development of a preliminary questionnaire. Looking at
the literature search results, it became obvious that no issues
could be derived from previous studies in AA patients. Even
the recent large seminal trial comparing horse and rabbit ATG
for treatment of severe and very severe aplastic anemia includ-
ing 120 patients did not cover quality of life [21].
The situation for patients with PNH is somewhat better in
that both the EORTC QLQ-C30 and the FACIT-Fatigue in-
struments have been used to evaluate quality of life in patients
treated with the complement inhibitor eculizumab [11, 12] and
are now used routinely for patients enrolled into the
International PNH registry [15]. This enabled researchers to
come up with the first real-life data about patients with PNH
demonstrating that these patients indeed experience a lower
global health status compared to the general population [15].
This publication also showed that suffering from PNH leads to
problems at patients’ workplace and repeated hospitalizations
in a proportion of patients mirroring the chronicity of the
disease under targeted treatment.
So far, only one survey evaluated the applicability of the
QLQ-C30 (and the FACIT-Fatigue) instrument in patients with
PNH [14] and [40]. In this study, the 29 patients from Spain,
France, the UK, and the USA agreed that the FACIT-Fatigue
instrument was highly relevant and adequate in assessing the
level of fatigue of which all but one of the patients complained;
Table 3 Patient characteristics of
the patients interviewed during
phases I and II
Phase I (n = 19) Phase II (n = 30)
Sex
Female 15 (79%) 15 (50%)
Male 4 (21%) 15 (50%)
Diseasea
PNH 4 (21%) 10 (33%)
AA 9 (47%) 10 (33%)
AA/PNH 6 (32%) 10 (33%)
Previous therapiesa
BMT 3 (16%) 2 (7%)
CSA 13 (68%) 20 (67%)
ATG 13 (68%) 17 (57%)
eculizumab 6 (32%) 15 (53%)
Age at diagnosis (in years)a
Median; mean; range 29.1; 30.7; 17.0–50.3 31.3; 43.2; 13.9–60.3
Age at the time of interview (in years)
Median; mean; range 42.1; 40.7; 25.1–61.3 43.7; 43.3; 18.9–73.5
Time from first symptoms until first physician contact
(in months)a
Median; mean; range 0; 9; 0–56 0; 3; 0–24
Time from first physician contact to final diagnosis
(in months)a
Median; mean; range 5; 14; 0–56 2; 6; 0–37
CSA Cyclosporin A, BMT bone marrow transplantation, ATG Antithymocyte Globulin
a Self-reported
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however, the QLQ-C30 was rated as being not as relevant in
assessing other quality of life aspects. While the authors stated
that their Bstudy confirms the validity of the FACIT-Fatigue and
the EORTCQLQ-C30 questionnaires in this patient population
and their routine use should be considered in the management
of patients with PNH,^ the results of our interviews and the
comparison of the derived issues with the items of the QLQ-30
underline that QoL aspects of patients with PNH and/or AA
seem to be inappropriately captured with available EORTC-
QoL tools. Even the EORTCQuality of life group (QLG) states
that Bwhile the EORTC QLQ-C30 is an important tool for
assessing the generic aspects of QoL, it has limitations^ and
Bthat it should be supplemented by additional modules^
(S126–S128 in [13]). This has been successfully carried
out for 17 malignancies including colorectal carcinoma,
multiple myeloma, breast cancer and others. However,
all these disease entities are cancers, and their incidence
is markedly higher than AA and/or PNH.
We found several new QoL aspects such as Bconstant fear
of infection^ and fear of Bvariations of blood counts,^
Bdependency on time-consuming therapies,^ and Bemotional
strain through endlessness of disease^ that are relevant for a
majority of AA/PNH patients. It therefore proved useful to
continue with the development of an AA/PNH-specific QoL
questionnaire.We used the well-established EORTC question-
naire development guidelines [25] for creating a specific and
comprehensive QoL questionnaire for patients with two non-
malignant hematologic diseases, though non-malignant is a
somewhat misleading term for AA and PNH as it is known
that the mortality and morbidity of these bone marrow failure
Table 4 Comparison of issues from phase I with items from the EORTC QLQ-C30 questionnaire
EORTC QLQ-C30 items Patient rating (mean; median)
Mentioned and rated important
1. Do you have any trouble doing strenuous activities, like carrying a heavy shopping bag or a suitcase? 3.2; 3.0
2. Do you have any trouble taking a long walk? 2.6; 3.0
3. Do you need to stay in bed or a chair during the day? 2.3; 2.0
4. Were you limited in doing either your work or other daily activities? 2.4; 2.0
5. Were you limited in pursuing your hobbies or other leisure time activities? 2.4; 2.0
6. Were you short of breath? 2.9; 3.0
7. Did you need to rest? 3.3; 4.0
8. Have you had pain? 2.5; 3.0
9. Did pain interfere with your daily activities? 2.3; 3.0
10. Have you had trouble sleeping? 2.2; 2.0
11. Have you felt weak? 2.6; 3.0
12. Were you tired? 3.1; 3.0
13. Have you had difficulty in concentrating on things, like reading a newspaper or watching television? 2.4; 2.0
14. Did you feel tense? 2.3; 2.0
15. Did you worry? 2.7; 3.0
16. Did you feel depressed? 2.4; 2.0
Mentioned and rated unimportant
1. Do you have any trouble taking a short walk outside of the house? 1.8; 1.0
2. Do you need help with eating, dressing, washing yourself or using the toilet? 1.2; 1.0
3. Have you felt nauseated? 1.6; 1.0
4. Have you had diarrhea? 1.5; 1.0
5. Has your physical condition or medical treatment caused you financial difficulties? 1.9; 1.0
6. Has your physical condition or medical treatment interfered with your social activities? 1.7; 1.0
7. Has your physical condition or medical treatment interfered with your family life? 1.7; 1.0
Not mentioned
1. Have you lacked appetite? n.a.
2. Have you vomited? n.a.
3. Have you been constipated? n.a.
4. Did you feel tense? n.a.
5. Have you had difficulty remembering things? n.a.
n.a. not applicable
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syndromes is comparable to those of malignant hematologic
diseases such as chronic myeloid leukemia (CML), multiple
myeloma (MM), or some forms of non-Hodgkins lymphoma
(NHL), especially in the era of targeted and individualized
therapies [40].
The fact that twelve of the QLQ-C30 items were not rated
relevant or not even mentioned at all despite the fact that
during phases I and II 49 AA/PNH patients and 17 physicians
with long-time experience in medical care of these patients
were thoroughly questioned shows that there clearly is a dif-
ference between cancer patients and our patient group. In ad-
dition, while it was planned to develop a QoL questionnaire
with a maximum of 30 to 35 items, patients and physicians
rated 77 issues concerning health-related quality of life as
being so important that they should be included into the pre-
final instrument.
Only a few issues were rated differently between patients
with AA and PNH. The Bfear of therapy failure^ as being the
one issue rated high by AA patients, while almost being ig-
nored by PNH patients reflects the different treatment modal-
ities with IST being applied to AA patients unfortunately still
has a failure rate of almost 30% with a cumulative incidence
of relapse in up to 28% of patients despite the high rate of
primary responders of almost 70% at 6 months in patients
treated with horse ATG and CSA [21].
The issues being rated significantly higher in patients with
PNHmostly reflect the problems faced by a patient group with
a chronic disease under a treatment that effectively tackles the
disease without causing a real cure as is the fact with the
complement inhibitor eculizumab. Eculizumab effectively re-
lieves symptoms and prevents morbidity and mortality
through prevention of hemolysis and thrombosis; however, it
does so by inhibiting complements effector phase but does not
alter the primary GPI deficiency [41]. Thus, patients have to
receive regular eculizumab infusions every 2 weeks and while
often experience an amelioration of their symptoms and gen-
eral performance status, they still have to face psychosocial
strain in communication with their friends and relatives and
even more so with the legislative social system when it comes
to provisioning of unemployment and healthcare benefits.
This is also reflected in the fact that the rating of issues by
patients and physicians directed us to come up with 20 issues,
which mainly covered healthcare issues and did not concern
physical quality of life issues. It is noteworthy that these extra
20 issues came up while we were asking explicitly for QoL
concerns of the patients. Our assumption is that this is due to
the rarity of the disease, which makes it especially difficult for
the patients to find adequate treatment and care.
The differences between AA and PNH patients, however,
were not that substantial that it would be advisable to create
two different questionnaires for the two disease entities.
Taken together, the first and second phase of this study
clearly demonstrated the need for an AA/PNH-disease-
specific QoL tool and the feasibility of developing such a tool
by using slightly modified EORTC guideline development
specifications. The support of patient advocacy groups in such
project with ultra-rare diseases proved especially helpful.
In phase III, the questionnaire will now be pilot-tested.
Eventually, the QLQ-AA/PNH questionnaire will be validated
and psychometrically tested (phase IV).
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